FULL YEAR 2018 RESULTS
FULL YEAR 2018 SALES
WORLDWIDE INCREASED
$81.6B 6.7% Excluding acquisitions/divestitures on an operational basis worldwide sales INCREASED 5.5%*

DILUTED EARNINGS PER SHARE
$5.61 ADJUSTED DILUTED EARNINGS PER SHARE*
$8.18 INCREASED 12.1%*

“Johnson & Johnson delivered another year of strong operational sales growth of 6.3% and achieved our 35th consecutive year of adjusted operational earnings growth at 9.8% in 2018. This can be attributed to accelerated underlying sales performance across each of our businesses, where we also leveraged our scale across the enterprise to improve margins. Looking ahead, the strength of our broad-based business and disciplined approach to portfolio management positions us to continue to fuel investments in innovation that enable us to capitalize on strategic opportunities and deliver strong performance over the long-term. Our performance is the result of our talented Johnson & Johnson colleagues and their extraordinary dedication to help advance health and well-being for patients and customers around the world.”

WORLDWIDE CONSUMER SALES
$13.9B
Consumer worldwide sales increased: 1.8%
Primary contributors to growth:

WORLDWIDE PHARMACEUTICAL SALES
$40.7B
Pharmaceutical worldwide sales increased: 12.4%
Primary contributors to growth:

WORLDWIDE MEDICAL DEVICES SALES
$27.0B
Medical Devices worldwide sales increased: 1.5%
Primary contributors to growth:


*Non-GAAP financial measures. See “GAAP Financial Measures” at the beginning of this release for a reconciliation of the non-GAAP financial measure to the most directly comparable GAAP financial measure.

Caution Concerning Forward-Looking Statements: This document contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including those statements relating to Johnson & Johnson’s anticipated business and financial performance. These statements are subject to risks and uncertainties that could cause actual results to vary materially from those anticipated or expressed in these forward-looking statements, which are based on current expectations of future events. For important information about the facts and circumstances that could cause actual results to vary materially from those anticipated or expressed in these forward-looking statements, please refer to the “Risk Factors” Forward-Looking Statements included in the Johnson & Johnson earnings releases based on January 22, 2019, as well as the most recently filed Johnson & Johnson Reports on Forms 10-K and 10-Q. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.